[Bone scintigraphy and rhenium radioisotope management in the course of metastatic prostatic cancer].
A 78-year-old patient with prostate cancer and osseous metastases had a pain symptomatic. In the Urology he was treated with antiandrogenes. The outcome of the bone scintigraphy showed a super bone scan with normalization after antiandrogene-therapy which seemed to be a sign of remission, before he showed a progressive form with multiple osseous metastases. Pain could not be treated with non steroidal antiphlogistics and opiates, so the indication for treatment with Rhenium-186-HEDP was given in this case.
Ostwald
E
E
Klinik für Nuklearmedizin, RWTH Aachen, Deutschland.
Sabri
O
O
Cremerius
U
U
Jakse
G
G
Büll
U
U
D000368:Aged; D000726:Androgen Antagonists / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000000981:diagnostic imaging* / Q000556:secondary*; D018450:Disease Progression; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D010146:Pain; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy* / Q000503:physiopathology; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D013669:Technetium Tc 99m Medronate / Q000031:analogs & derivatives
D000726:Androgen Antagonists; D019275:Radiopharmaceuticals; C024226:technetium Tc 99m hydroxymethylene diphosphonate; D013669:Technetium Tc 99m Medronate
Skelettszintigraphie und Radio-Rhenium-Behandlung im Verlauf eines metastasierenden Prostatakarzinoms.